Skye Bioscience, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.00
- 52-Week Range
- $0.50 – $11.04
- Market Cap
- $4.56M
- P/E (TTM)
- —
- EPS (TTM)
- -7.56
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.21
- PEG Ratio
- —
- Return on Equity
- -233.87%
- Return on Assets
- -95.06%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 0.95
- Debt/Equity
- —
- Total Debt
- $178.75K
- Free Cash Flow
- $-18.71M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-5.06M
Market Snapshot
About
Skye Bioscience, Inc. is a clinical-stage pharmaceutical company developing cannabinoid-based therapies. The company focuses on treating metabolic diseases such as obesity and related metabolic disorders. Skye is advancing its lead compound through clinical trials for various indications.